NASDAQ:AMGN
Amgen Inc. (AMGN)
Financials 
Technical Analysis 
Jul 5, 2026, 12:00 amThis summary was created by AI, based on 17 opinions in the last 12 months.
Amgen Inc. (AMGN) is highly regarded among experts for its stable management and well-executed innovative pipeline, featuring 15 products that have demonstrated double-digit revenue growth. Multiple analysts highlight the company's promising GLP-1 weight-loss drug currently in phase 3 testing, pointing to its potential as a game-changer in the market. Despite some concerns about slower growth compared to peers, many see AMGN as a safer investment within the biotech sector, especially given its reasonable forward P/E ratio below 20x and attractive dividend yield, which is around 3.23% to 3.46%. The stock appears to be breaking out to new highs and has recently been upgraded, reinforcing the belief in its upward trajectory as the industry evolves. Overall, AMGN is considered a solid holding for investors looking for exposure to large-cap biotech, particularly with strong earnings potential and an optimistic outlook steering toward 2027.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium content
He's surprised with how strongly shares are soaring on phase 3 trial results of their obesity drug. They're a little late to the party in these drugs, but theirs you would take less often their than peers'. Also, a recent acquisition makes them double-digit revenue growers and is accretive. Loves the dividend growth too.
Kevin SimpsonLegacy products that continue to do well. But new products are contributing well, too. Latest acquisition adding significantly to growth profile. Reasonable multiple of 12-13x, good prospects for growth. Out of favour, along with many healthcare stocks. Good, long-term hold.
Premium contentAs AI begins to play a larger role in medical intervention, AMGN is well positioned to benefit. It has increased its dividend for 11 consecutive years. It trades at 21x earnings and supports a robust 135% ROE. We recommend setting a stop-loss at $210, looking to achieve $319 -- upside potential of 18%. Yield 3.2%
(Analysts’ price target is $308.33)His impression was that the Phase 1 trial did go well. Management emphasized long way to go before it would have a monetary impact. Stock did sell off when earnings released. Still likes it. Recent acquisition will be positive for future earnings and revenue growth. Not expensive. Lots in pipeline.
Gordon ReidDrop mainly due to NVO and LLY leading the pack on weight-loss drugs. Still, AMGN has a great lineup of drugs, revenues should grow over time. Ranks well for him. More beta than a normal healthcare stock. Now at 100-day MA, almost oversold. Makes sense from an earnings growth perspective, high single digits. Fine name, he just prefers others.
Down a bit on earnings report this morning, but overlook that, short-term reaction. Phase 1 weight-loss drug primed to compete with LLY's, though not yet being promoted as its next blockbuster. Much more modest multiple than LLY.
Gordon ReidReasonable multiple, mid-high teens. Good growth rate, highly predictable. Has a GLP-1 candidate, good results in Phase 1 testing. 17% of revenue goes back into R&D.
Gordon Reid
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Owns this instead of NVO. A much less troublesome valuation. Also has a weight-loss drug in trial. You want to be in before the good news, not after.